Imagine a device that could diagnose brain injury almost immediately after severe head trauma by measuring the proteins released after impact. BioDirection, a Boston-based startup, is building that tool, and funding from a $4 million Series B round is going to help.
BioDirection's system, called Tbit, is portable and uses a nanotechnology sensor. The company is betting it will reduce the need for unnecessary CT scans and help patients with head injuries get the correct diagnosis and treatment faster.
This round brings the company's total funds raised to $10 million, which BioDirection says it will use to speed up the final development stages of Tbit and begin the commercialization process. Provident Healthcare Capital led the round.